StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M) ($M)

Form 6-K / 20-F Therapy Area Product Sales Table

QuarterlyAnnual
Latest, Q2 2026
1,346
Period ended Jun 30, 2026
Change on a year earlier
-11.0%
1,512 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,346-11.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20261,653+6.5%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20251,270+6.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20251,559+11.7%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20251,512+9.2%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20251,552+13.7%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20241,193+10.7%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20241,396+20.2%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20241,384+17.1%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20241,365+17.2%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20231,078+14.9%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20231,161+7.4%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20231,182+10.1%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20231,165+13.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022938+8.1%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20221,081+9.1%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up cardiovascular, renal & metabolism (cvrm) — emerging markets product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_cvrm_em

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.